Stryker Corp (SYK) Stock Analysis

Verdict: WATCH (do not buy)

Operational delays in peripheral vascular manufacturing threaten near-term growth, but strong 65% gross margins offer long-term value.

Investment score: 54/100

Analysis as of

Is Stryker Corp stock worth reviewing? AI model thesis

The model sees Stryker trading near fair value at $282.55 as operational headwinds in its peripheral vascular business obscure robust 65.3% gross margins.

7-factor investment score

Stryker Corp opportunities and risks

What speaks for SYK

What speaks against SYK

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
SYK29.1x4.2x17.9x65.2%14.4%4.3%
ABT32.9x3.8x18.1x56.8%11.6%4.9%
ISRG47.6x13.5x32.2x66.7%28.4%2.2%
BSX17.5x3.1x13.2x71.2%17.5%5.6%
BDX56.4x2.5x15.2x46.1%4.5%5.0%
EW49.2x7.6x29.8x78.0%15.4%2.9%
Peer median47.6x3.8x18.1x66.7%15.4%4.9%

Frequently asked questions about Stryker Corp (SYK)

Is SYK stock a good investment?

The cached TradeMates AI model rates Stryker Corp as WATCH (do not buy) with an investment score of 54/100. The model sees Stryker trading near fair value at $282.55 as operational headwinds in its peripheral vascular business obscure robust 65.3% gross margins. This is algorithmic model output, not personal investment advice.

Is SYK stock a buy?

The TradeMates model verdict for SYK is WATCH (do not buy) with an investment score of 54/100. Treat this as a model signal to review, not a personal buy recommendation.